Table 2: Preliminary safety data from the BRIGHT study.

n (%)	Gla-300 (n=462)	IDeg (n=462)
Participants with any TEAE	202 (43.7)	221 (47.8)
Participants with any TE SAE	21 (4.5)	20 (4.3)
Participants with any TEAE leading to death	1 (0.2)	0 (0.0)
Participants with any TEAE leading to permanent treatment discontinuation	4 (0.9)	5 (1.1)

Gla-300 = insulin glargine 300 U/mL; IDeg = insulin degludec; SAE = serious adverse event; TE = treatment-emergent; TEAE = treatment-emergent adverse event. Reproduced with permission from: Cheng et al., 2018.¹⁰